ClinicalTrials.gg
Not yet recruitingNCT07863336ALSO-PERFORMUpdated Oct 8, 2026

ALSO-PERFORM Study. ALternating Stereotaxic Or PElvic Radiotherapy FOR Metachronic Metastatic Prostate Cancer

An observational study in Prostate Cancer, sponsored by Amsterdam UMC, location VUmc. Not yet recruiting. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Amsterdam UMC, location VUmc · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years to 99 Years
Sex
Male
01

Study summary

Outcome of metastasis directed therapy

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 130 is below the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Men with histologically confirmed prostate cancer who have undergone radical prostatectomy, have experienced biochemical (PSA) recurrence, and have lymphogenic metastases in the pelvic region on PSMA PET/CT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men with confirmed prostate cancer
  • Men who have undergone radical prostatectomy (RP), with or without extended pelvic lymph node dissection (ePLND)
  • Men with pNx or pN0 status in the ePLND specimen
  • Biochemical recurrence after RP (PSA > 0.2 ng/mL on two occasions)
  • Evidence of lymphogenic on staging PSMA PET/CT within the pelvis (below the aortic bifurcation)
  • ≥ 5 years, as estimated by the treating physician

Exclusion criteria

Exclusion Criteria:

  • Previous salvage radiotherapy to the prostate bed
  • Men with lymph node outside the pelvis (M1a)
  • Men with osseous metastases (M1b) or visceral metastases (M1c)
  • Men with lymphogenic metastases and a local recurrence
  • Men with inguinal metastases
  • Previous treatment in the pelvic region, such as treatment of the bladder or rectum, that precludes radiotherapy to the pelvis
  • Previous treatment with an LHRH agonist/antagonist within 6 months prior to study inclusion. Patients must have normal testosterone levels (testosterone > 7.0 nmol/L)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. The primary endpoint is the number of patients (and percentage of the total) with metastases on PSMA PET/CT two years after study initiation.

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 11 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863336
Collaborators
Accord Healthcare, Inc.
Responsible party
Prof. Dr. André N. Vis (Prof Dr., Amsterdam UMC, location VUmc) — Principal investigator
First posted
Oct 7, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion